Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.300 Biomarker disease CTD_human Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer. 21716162 2011
CUI: C0013146
Disease: Drug abuse
Drug abuse
0.010 GeneticVariation group BEFREE The described drug abuse cases suggest that an association between the presence of CYP2C and VKORC1 allelic variants and cocaine-induced interstitial lung damage is highly likely. 21766908 2011
Diabetes Mellitus, Non-Insulin-Dependent
0.030 Biomarker disease BEFREE CYP2C enzymes are responsible for the oxidative metabolism of a diverse number of drugs for the treatment of type 2 diabetes mellitus, a severe metabolic disorder with high prevalence. 21939641 2011
CUI: C0025517
Disease: Metabolic Diseases
Metabolic Diseases
0.020 Biomarker group BEFREE CYP2C enzymes are responsible for the oxidative metabolism of a diverse number of drugs for the treatment of type 2 diabetes mellitus, a severe metabolic disorder with high prevalence. 21939641 2011
CUI: C0030920
Disease: Peptic Ulcer
Peptic Ulcer
0.010 GeneticVariation disease BEFREE We investigated whether eight functional SNPs in the CYP2C family of genes--CYP2C8*3 (rs11572080 and rs10509681), CYP2C8*4, CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C19*3, and CYP2C19*17--are associated with PUD in 1,239 Caucasian patients. 23267857 2013
CUI: C0035309
Disease: Retinal Diseases
Retinal Diseases
0.020 AlteredExpression group BEFREE We found that CYP2C (localized in wild-type monocytes/macrophages) is upregulated in oxygen-induced retinopathy, whereas sEH is suppressed, resulting in an increased retinal epoxide:diol ratio. 24458713 2014
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.040 Biomarker group BEFREE Studies with rat genetic models of hypertension pointed to roles for the CYP2C and CYP4A arachidonic acid epoxygenases and ω-hydroxylases in tubular transport, hemodynamics, and blood pressure control. 25986599 2015
CUI: C0035309
Disease: Retinal Diseases
Retinal Diseases
0.020 PosttranslationalModification group BEFREE Soluble epoxide hydrolase inhibition, which blocks breakdown and inactivation of CYP2C ω-3 LCPUFA-derived active metabolites, increased oxygen-induced retinopathy and CNV in vivo. 27417579 2016
CUI: C0015397
Disease: Disorder of eye
Disorder of eye
0.010 AlteredExpression group BEFREE We hypothesized that inhibition of CYP2C activity will add to the protective effects of ω-3 LCPUFA on neovascular eye diseases. 27417579 2016
CUI: C0272051
Disease: Xerocytosis
Xerocytosis
0.010 GeneticVariation disease BEFREE Non-genetic factor, omeprazole co-medication, was strongly associated with PHT-induced DRESS/DHS in addition to variants in HLA-B and CYP2C genes. 28391407 2017
CUI: C1844680
Disease: DEAFNESS-HYPOGONADISM SYNDROME
DEAFNESS-HYPOGONADISM SYNDROME
0.010 GeneticVariation disease BEFREE Non-genetic factor, omeprazole co-medication, was strongly associated with PHT-induced DRESS/DHS in addition to variants in HLA-B and CYP2C genes. 28391407 2017
CUI: C3541994
Disease: Drug Hypersensitivity Syndrome
Drug Hypersensitivity Syndrome
0.010 GeneticVariation disease BEFREE Non-genetic factor, omeprazole co-medication, was strongly associated with PHT-induced DRESS/DHS in addition to variants in HLA-B and CYP2C genes. 28391407 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.040 Biomarker group BEFREE The contribution of CYP2C gene subfamily involved in epoxygenase pathway of arachidonic acids metabolism to hypertension susceptibility in Russian population. 28513222 2017
CUI: C0085580
Disease: Essential Hypertension
Essential Hypertension
0.010 GeneticVariation disease BEFREE Thus, genes of CYP2C subfamily are important genetic determinants of susceptibility to essential hypertension in Russians. 28513222 2017
CUI: C0010068
Disease: Coronary heart disease
Coronary heart disease
0.010 GeneticVariation disease BEFREE Our preliminary results demonstrate that polymorphisms of genes encoding CYP2C subfamily represent potential genetic markers of CHD susceptibility. 28687336 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.040 GeneticVariation group BEFREE Overall, nifedipine and verapamil blunts CSA hypertension but variably affected concomitantly enhanced EDHF-dependent renal vasodilations and alterations in CYP2C/CYP4A signaling. 28899749 2017
Diabetes Mellitus, Non-Insulin-Dependent
0.030 AlteredExpression disease BEFREE Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues. 28954402 2017
Diabetes Mellitus, Non-Insulin-Dependent
0.030 Biomarker disease BEFREE These alterations induced by Type II diabetes in the endogenous pathway (CYP450) of arachidonic acid metabolism may increase the risk for cardiovascular disease by disrupting the fine equilibrium between cardioprotective (CYP2J/CYP2C-generated) and cardiotoxic (CYP4A/CYP4F-generated) metabolites of arachidonic acid. 29023376 2017
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.010 GeneticVariation group BEFREE These alterations induced by Type II diabetes in the endogenous pathway (CYP450) of arachidonic acid metabolism may increase the risk for cardiovascular disease by disrupting the fine equilibrium between cardioprotective (CYP2J/CYP2C-generated) and cardiotoxic (CYP4A/CYP4F-generated) metabolites of arachidonic acid. 29023376 2017
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.010 AlteredExpression disease BEFREE This study indicated that the presence of UC decreases CYP2C expression levels in the liver, thereby delaying the metabolism of CYP2C substrates, including phenytoin, and increasing blood concentrations of these substrates. 29130833 2018
CUI: C0014518
Disease: Toxic Epidermal Necrolysis
Toxic Epidermal Necrolysis
0.010 AlteredExpression disease BEFREE Further multicenter studies and large prospective observational studies are, however, still required to determine the influence of CYP2C*3 on blood levels of PHT and its metabolites, and their association with SJS/TEN. 29274302 2018
CUI: C0036391
Disease: Schwartz-Jampel Syndrome
Schwartz-Jampel Syndrome
0.010 AlteredExpression disease BEFREE Further multicenter studies and large prospective observational studies are, however, still required to determine the influence of CYP2C*3 on blood levels of PHT and its metabolites, and their association with SJS/TEN. 29274302 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.020 AlteredExpression disease BEFREE This study investigated the prognostic value of CYP2C subfamily gene expression levels with HCC prognosis. 29479826 2018
CUI: C0236734
Disease: Caffeine related disorders
Caffeine related disorders
0.010 Biomarker group BEFREE The five probe substrates were caffeine (2 mg/kg), bupropion (30 mg/kg), omeprazole (4 mg/kg), dextromethorphan (40 mg/kg), and midazolam (2 mg/kg) for CYP1A, CYP2B, CYP2C, CYP2D, and CYP3A, respectively. 29550976 2018
CUI: C0008370
Disease: Cholestasis
Cholestasis
0.010 AlteredExpression disease BEFREE The constitutive androstane receptor (CAR)/pregnane X receptor (PXR)-CYP2B/CYP2C axis is activated in DKO livers but not in other cholestasis models. 29718219 2018